Koklesova Lenka, Jakubikova Jana, Cholujova Dana, Samec Marek, Mazurakova Alena, Šudomová Miroslava, Pec Martin, Hassan Sherif T S, Biringer Kamil, Büsselberg Dietrich, Hurtova Tatiana, Golubnitschaja Olga, Kubatka Peter
Clinic of Obstetrics and Gynecology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia.
Cancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
Front Pharmacol. 2023 Mar 23;14:1121950. doi: 10.3389/fphar.2023.1121950. eCollection 2023.
Cancer causes many deaths worldwide each year, especially due to tumor heterogeneity leading to disease progression and treatment failure. Targeted treatment of heterogeneous population of cells - cancer stem cells is still an issue in protecting affected individuals against associated multidrug resistance and disease progression. Nanotherapeutic agents have the potential to go beyond state-of-the-art approaches in overall cancer management. Specially assembled nanoparticles act as carriers for targeted drug delivery. Several nanodrugs have already been approved by the US Food and Drug Administration (FDA) for treating different cancer types. Phytochemicals isolated from plants demonstrate considerable potential for nanomedical applications in oncology thanks to their antioxidant, anti-inflammatory, anti-proliferative, and other health benefits. Phytochemical-based NPs can enhance anticancer therapeutic effects, improve cellular uptake of therapeutic agents, and mitigate the side effects of toxic anticancer treatments. Per evidence, phytochemical-based NPs can specifically target CSCs decreasing risks of tumor relapse and metastatic disease manifestation. Therefore, this review focuses on current outlook of phytochemical-based NPs and their potential targeting CSCs in cancer research studies and their consideration in the framework of predictive, preventive, and personalized medicine (3PM).
癌症每年在全球导致许多人死亡，特别是由于肿瘤异质性导致疾病进展和治疗失败。针对异质性细胞群体——癌症干细胞进行靶向治疗，在保护患者免受相关多药耐药性和疾病进展方面仍是一个问题。纳米治疗剂在整体癌症管理方面有可能超越现有方法。特殊组装的纳米颗粒可作为靶向药物递送的载体。几种纳米药物已被美国食品药品监督管理局（FDA）批准用于治疗不同类型的癌症。从植物中分离出的植物化学物质因其抗氧化、抗炎、抗增殖和其他健康益处，在肿瘤学纳米医学应用中显示出巨大潜力。基于植物化学物质的纳米颗粒可以增强抗癌治疗效果，提高治疗剂的细胞摄取，并减轻有毒抗癌治疗的副作用。根据现有证据，基于植物化学物质的纳米颗粒可以特异性地靶向癌症干细胞，降低肿瘤复发和转移性疾病表现的风险。因此，本综述重点关注基于植物化学物质的纳米颗粒的当前前景，及其在癌症研究中靶向癌症干细胞的潜力，以及在预测、预防和个性化医学（3PM）框架中的考量。
